A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody

Mirjam TW van der Sluijs¹, Eva M Kuhn², Birgit Makoschey³*

Abstract

Background: The efficacy of a single dose of an inactivated bovine respiratory syncytial virus (BRSV) - Parainfluenza type 3 (PI3) - Mannheimia haemolytica (Mh) combination vaccine, in calves positive for maternal antibodies, was established in a BRSV infection study.

Results: As expected the single vaccination did not have any effect on the decline of BRSV-specific neutralising or ELISA antibody. The cellular immune system was however primed by the vaccination. In the vaccinated group virus excretion with nasal discharge was reduced, less virus could be re-isolated from lung tissues and the lungs were less affected.

Conclusions: These results indicate that a single vaccination with an inactivated BRSV vaccine was able to break through the maternal immunity and induce partial protection in very young calves. It can be speculated that the level and duration of protection will improve after the second dose of vaccine is administered. A two-dose basic vaccination schedule is recommended under field conditions.

Background

The bovine respiratory syncytial virus (BRSV) has been established as an important viral component in the bovine respiratory disease complex (BRDC) [1]. The virus can act synergistically with other viruses such as the bovine parainfluenza type 3 virus (PI3) or bacteria such as Mannheimia haemolytica (Mh), Pasteurella multocida, Haemophilus somnus and Mycoplasma bovis to cause pneumonia [2]. BRSV also fulfils the Koch’s postulates to be recognised as an aetiologic agent of pneumonia in calves. Respiratory disease is however often milder under laboratory conditions than under field conditions [3-6].

Outbreaks of BRSV associated pneumonia typically recur every year [7] and most farms are affected. The mechanisms for the persistence of the virus in a farm are not well understood [8]. Based on sequence divergence among BRSV isolated during recurrent outbreaks in closed herds, (re)introduction of the virus into the herd prior to each new outbreak is the most likely explanation [9]. Airborne transmission of BRSV has been demonstrated under experimental conditions [10].

Different approaches have been followed to develop safe and efficacious BRSV vaccines including inactivated vaccines [11,12], (genetically) modified live vaccines [11,13], subunit vaccines [14], DNA vaccines [15] and vector vaccines [16,17]. Today inactivated and modified live BRSV vaccines are commercially available, most of them as combination vaccine with other antigens related to the BRDC.

The basic vaccination schedule for inactivated BRSV vaccines consist of two doses of 5 ml each, applied by subcutaneous injections, at an interval of 3 to 4 weeks. Remarkably most cases of severe BRSV are observed in calves aged 1-3 months, at which time they still possess maternal antibodies [18]. In order to provide efficacious protection against BRSV at this very young age it is essential that vaccines are able to overcome the
interference of maternal antibodies and confer protection shortly after vaccination. Due to the high risk of BRSV associated pneumonia in the very young age group, it is also of great value to evaluate the level of immunity induced by the first vaccination before completion of the full primary course has taken place. The inactivated BRSV-PI3-Mh combination vaccine used in the study reported here has previously been shown to reduce the severity of clinical signs and virus shedding in two-week-old MDA (+) calves that had received a primary course of two vaccinations four weeks apart. The calves were challenged with BRSV 3 weeks after the second vaccination. Moreover, in a previous study with the same vaccine, the efficacy in terms of antibody response and clinical protection has been established after application of a single dose of the vaccine to 4-5 week old calves with maternal antibodies [19]. In the study reported here two week old calves with maternal antibodies were vaccinated with a single dose, antibody levels as well as cellular immunity was measured. As it was expected that the maternal antibodies would interfere with the induction of clinical signs, lung pathology was used as a parameter to evaluate protection.

Methods

Animals
Ten Holstein crossbred calves were included in the study. They were removed from the dam directly after birth in order to prevent infection with BRSV or other pathogens. The calves were fed pre-collected colostrums with high antibody titres against BRSV in order to obtain similar antibody titres in all calves. The animals were identified by means of numbered ear tags. They were ranked by age and then allocated, on an alternating basis, to one of the two treatment groups in order to obtain the same average age for both groups. The complete study was undertaken in a blinded manner.

From the week before vaccination and onwards the calves were housed, separated by group, in two different rooms of an isolation unit. Strict barrier conditions between the two groups were maintained by means of individual filtered air supply to each room, sealed doors and by staff changing cloths and showering between the rooms.

One calf allocated to the control group had to be euthanised because of a persistent inflammation of the carpal joint before challenge.

All procedures were approved upfront by the Animal Care and Use Committee according to the Dutch animal welfare regulations.

Vaccination
A commercial batch of an inactivated combined BRSV, PI3 and Mh vaccine with alhydrogel and Quil A as adjuvants (Bovilis Bovipast RSP, Intervet/Schering-Plough Animal Health) was used. Five calves were given a single dose of 5 ml by the subcutaneous route into the neck. A second group of 5 calves was not vaccinated. The average age of the calves at the time of vaccination was two weeks.

Challenge
Four weeks after they had been vaccinated, all calves were challenged by aerosolisation with a wild-type strain of BRSV (CA-1, kindly provided by L. Gershwin) as described earlier [13]. The challenge dose was \(10^{5.9}\) TCID\(_{50}\) in a 10 ml volume.

Assessment of clinical signs
From two days prior to challenge until the end of the study the calves were observed daily for clinical reactions and the body temperature was recorded. Special attention was paid to signs of respiratory disease such as coughing - spontaneous and stimulated (by palpation of the larynx), nasal or ocular discharge and respiratory rate.

Serology
To determine the calves’ antibody response to vaccination and challenge, blood samples were taken at vaccination (day 0), just before challenge (day 28) and one week later (day 35). Serum samples were assayed for BRSV specific antibody by serum neutralising (VN) antibody and ELISA antibody.

The VN test was performed according to the end point dilution method in a microtitre format. Two-fold serial dilutions of the serum samples were incubated with a fixed amount of BRSV prior to the addition of Vero cells. After 5-7 days of culture, the plates were read for BRSV specific cytopathic effects. The VN titres were the reciprocal value of the highest dilution in which complete neutralisation of the virus was obtained. They were expressed as \(\log_2\).

An in-house BRSV blocking ELISA was performed. Plates were first coated with a BRSV specific monoclonal antibody and secondly with BRSV antigen. After appropriate washing steps, dilution series of the sera were incubated followed by the incubation of a second biotinylated monoclonal antibody. Avidin-peroxidase complexes were allowed to bind to the biotin. A standard colour reaction using 3,3’5,5’tetramethylbenzidine as substrate was performed to quantitate the amount of bound second antibody. Antibody titres were calculated from the blocking percentage.

Cellular immune response
A lymphocyte activation assay was performed on heparinised blood samples taken at days 0, 28 and 35. In 24-well plates heparinised blood samples (sample volume: 1 ml) were stimulated with Concanavalin A (Sigma Aldrich, 100 μl/ml blood) or lysate of BRSV infected MDBK cells. Negative control samples were treated similarly with culture medium or lysate of uninfected...
MDBK cells. After two days of incubation at 37°C Interferon γ (IFN γ) production was measured using a commercial ELISA (Bovine IFN γ EASIA, Biosource Europe S.A.) according to the manufacturer’s recommendations.

Nasal shedding of challenge virus
From two days prior to challenge until the end of the study nasal swab samples were taken daily from all calves by means of swab sticks containing a sterile cotton plug. Separate swabs were used for each animal. The swabs were gently rotated up and down the sides of both nasal cavities several times. The swabs were then inserted into a tube containing 1 ml of sterile phosphate buffered saline medium. The liquid was transferred into suitable containers and stored at temperatures below -70°C until tested.

Post mortem examination
At seven or 10 days after challenge the calves were sacrificed. The lungs were inspected macroscopically and representative samples of organs showing any changes were taken. The samples were fixed with formalin and then processed into paraffin embedded sections. These were stained with haematoxylin and eosin and investigated microscopically.

Additional samples for virus isolation were taken from nasopharyngeal mucosa, tonsils, submandibular lymph nodes, each lung lobe and mediastinal and bronchial lymph nodes.

Tracheobronchial lung washes were performed as follows. Both lungs were excised and flushed with 300 ml of saline. The fluid was recovered and stored at temperatures below -70°C until tested.

Titration of nasal swab samples and lung wash fluid for BRSV
The BRSV titre in nasal swab samples and lung wash fluid was determined according to the end point dilution method in a microtitre format. Five-fold serial dilutions of the samples were incubated on bovine embryo lung cells. Infection was evaluated by the development of BRSV specific cytopathic effects after 5-7 days of culture. Each sample was tested in quadruplicates.

Testing of tissue samples for BRSV
Homogenized samples were incubated in four-fold on a monolayer of Vero cells in 24-well plates. After 5-7 days of culture supernatants of the cultures were transferred onto fresh monolayers of Vero cells. The monolayers after the first and the second passage were read for BRSV specific cytopathic effects.

Statistical evaluation
The results were summarised using frequency tables. The Wilcoxon two-sample test was performed to compare: maximum titres in nasal swab samples, days of virus excretion and extinction values in the INFγ ELISA.

The above statistical tests were performed at 5% level of significance. The data analysis was done using SAS software, Version 8.2. Copyright© [1999-2001] by SAS Institute Inc., Cary, NC, USA.

Results

Clinical signs and body temperatures
Only minor clinical signs were observed. There were no increased respiratory rates; in fact the only clinical sign of respiratory disease was coughing of individual animals. One vaccinated animal showed stimulated coughing, during examination, at 6 and 7 days after challenge. Another vaccinated and one unvaccinated animal coughed spontaneously on days 8 through 10.

Throughout the experiment none of the calves developed a fever (body temperature above 39.5°C).

BRSV specific immune reaction

BRSV specific antibody response
All calves had moderate to high antibody titres at the start of the study (individual data not shown). The average VN and ELISA antibody titres at the time of vaccination in the vaccinated group were 9.6 log_{10} and 8.2 log_{10} (see table 1). These values are very similar to the average titres measured at the same time for the control animals (9.3 log_{10} and 8.3 log_{10} for VN and ELISA respectively). At the time of challenge (t = 28 days) and one week later (t = 35 days) the titres were at the same level or had dropped slightly for both groups.

BRSV specific cellular immune response
No cellular immune response, as determined in the lymphocyte stimulation assay, was detected at the time of vaccination (see table 2). At the time of challenge one out of five vaccinated animals was positive, all unvaccinated animals were negative.

One week after the challenge IFNγ production was measured in stimulated blood samples of four out of five vaccinated and one out of four unvaccinated control calves. The difference between the two groups was statistically significant (p < 0.05, Wilcoxon two-sample test).

Virus re-isolation from nasal swab samples
From day 4 to day 7 after infection BRSV could be re-isolated from nasal swab samples from three out of four unvaccinated animals. (table 3). Only two out of five vaccinated animals shed detectable but low levels of

| Parameter | VN antibody | ELISA antibody |
|-----------|-------------|----------------|
| Time (days) | 0 | 28 | 35 | 0 | 28 | 35 |
| Treatment group: | | | | | | |
| Vaccinated | 96 | 80 | 76 | 82 | 65 | 65 |
| Unvaccinated | 93 | 84 | 75 | 83 | 66 | 65 |

* Calves were infected intranasally with live BRSV 28 days after vaccination with one dose of the inactivated BRSV-PI3-Mh combination vaccine.
BRSV with nasal discharge on day 6 post-infection. The maximum titres and the number of days when virus was excreted was significantly lower in the vaccinated group as compared to the control group (p < 0.05, Wilcoxon two sample test.)

Gross and microscopic pathology findings
Macroscopic pathological findings differed substantially between the animals. No lung lesions were observed in the lungs of two vaccinated and one unvaccinated animal. Only minor lesions were present in the lungs of two vaccinated and two unvaccinated animals.

The lung of the fifth vaccinated animal showed dark red consolidation of 10-25% of the medial and apical lung lobes. In contrast, all lung lobes of the fourth unvaccinated animal were affected and 50% of the right apical lobe and 80% of the medial lobe were consolidated.

BRSV non-specific microscopic lesions were present in two vaccinated and three control animals. Syncytial cells, which are characteristic for BRSV infection, were present in two vaccinated animals and suspected in one control animal.

Isolation of BRSV from tissue samples and lung wash fluid
BRSV could be re-isolated from tissue samples out of the respiratory tract in four out of five vaccinated and all unvaccinated animals (see table 3). The number of positive samples was higher in the unvaccinated group (average 4.5) than in the vaccinated (2.0).

The lung wash fluid of one vaccinated and one unvaccinated animal, both killed 7 days after infection, was found positive for BRSV. All other samples were negative.

Discussion
The clinical signs observed after intranasal challenge with virulent BRSV were rather mild in the control animals and therefore no conclusion on clinical protection can be drawn from this study. The difficulty of reproducing BRSV associated disease under experimental conditions has been reported previously [3-6]. In the study reported here calves with maternally derived antibodies were used and the challenge was performed as early as 6 weeks of age. At that point maternal antibody levels were still moderate to high. These maternal antibodies are likely to interfere with the BRSV infection as reported by Kimman and colleagues [18]. For this reason BRSV vaccination-challenge studies reported in the literature were often either performed in older animals [19,20] or colostrum deprived calves [21], or the

| Treatment group | Animal | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|-----------------|--------|---|---|---|---|---|---|---|---|---|---|---|
| Vaccinated      | V1     | - | - | - | - | - | - | - | n.s. | n.s. | - | - |
|                 | V2     | - | - | - | - | - | - | - | 2.7 | n.s. | n.s. | - |
|                 | V3     | - | - | - | - | - | - | - | n.s. | n.s. | - | - |
|                 | V4     | - | - | - | - | - | - | - | 2.0 | - | - | - |
|                 | V5     | - | - | - | - | - | - | - | - | - | - | - |
| Control         | C1     | - | - | - | - | - | - | - | n.s. | n.s. | - | - |
|                 | C2     | - | - | - | - | - | 2.0 | 3.9 | 2.0 | n.s. | n.s. | n.s. |
|                 | C3     | - | - | - | - | - | 3.6 | 3.4 | 3.6 | - | - | - |
|                 | C4     | - | - | - | - | 3.2 | 3.8 | - | - | - | - | - |

* Calves were infected intranasally with live BRSV 28 days after vaccination with one dose of the inactivated BRSV-PI3-Mh combination vaccine.

*According to the information of the manufacturer of the assay, values above the cut-off level (0.207) have to be interpreted as positive - indicated by the bold letter type.

# Average values with different superscript letters are significantly different (p < 0.05) from each other.

Table 3 Individual BRSV infection titres [log10TCID50] in nasal swab samples in vaccinated and control calves after intranasal challenge with live BRSV

van der Sluijs et al. BMC Veterinary Research 2010, 6:2
http://www.biomedcentral.com/1746-6148/6/2
Table 4 BRSV isolation from tissue samples and lung wash fluid of vaccinated and control animals after intranasal infection with BRSV

| Treatment group | Animal | Post mortem on dpi* | Number tissue sample | BRSV titre in lung wash log10 TCID50/ml |
|-----------------|--------|---------------------|----------------------|----------------------------------------|
| Vaccinated      | V1     | 7                   | 1                    | -                                      |
|                 | V2     | 7                   | 5                    | -                                      |
|                 | V3     | 7                   | 0                    | 4.5                                    |
|                 | V4     | 10                  | 1                    | -                                      |
|                 | V5     | 10                  | 3                    | -                                      |
| Control         | C1     | 7                   | 6                    | -                                      |
|                 | C2     | 7                   | 5                    | 5.4                                    |
|                 | C3     | 10                  | 4                    | -                                      |
|                 | C4     | 10                  | 3                    | -                                      |

* dpi: days post infection

challenge was performed later after vaccination [22,23], alternatively a combination of these different approaches was applied. However an early challenge of young calves with moderate to high maternally derived immunity, as described in this study, reflects the field situation. Under these conditions it is very difficult but also very important for a BRSV vaccine to provide protection.

The vaccinated animals did not develop clinical signs other than provoked or spontaneous coughing in one animal. This observation is noteworthy since vaccine induced exacerbation of BRSV infections has been reported from field observations [24] and reproduced in the laboratory [25]. The pathophysiology of the disease in cattle was related to formalin inactivated BRSV. This is analogous to reports on human RSV enhancement after vaccination with formalin-inactivated RSV vaccine. The hypothesis is however not in line with the results of laborotary [25]. The pathophysiology of the disease in cattle was related to formalin inactivated BRSV. This is analogous to reports on human RSV enhancement after vaccination with formalin-inactivated RSV vaccine. The hypothesis is however not in line with the results of Mohanty and co-workers [26]. The vaccine used in this study also contained formalin-inactivated BRSV. The number of animals used here might be too low to allow general conclusions, however our results confirm earlier findings from laboratory studies [12,19] and unpublished field data that the vaccine does not enhance BRSV disease severity in naturally infected cattle.

In this experiment a single dose of the inactivated BRSV-P13-Mh combination vaccine did not have any effect on the decline of BRSV-specific neutralising or ELISA antibody. This result was expected and in line with other reports [19,20]. The role of different types of antibodies in protection against BRSV has been discussed in the literature [27]. Therefore, in this study, VN titres and ELISA titres were determined. However both types of antibody titres, VN and ELISA, followed the same profile e.g. animals with high VN titres also had high ELISA titres and vice versa. This finding indicates that the colostrums used to feed the calves were obtained from mothers with a similar history of BRSV vaccination and/or infection.

Earlier studies with the same vaccine have shown a clear booster response when the animals were given a second dose of vaccine [20] or infected with BRSV 3 weeks after a single dose of the vaccine [19]. In this study calves were euthanised for post mortem examination at 7 or 10 days post infection, therefore no booster antibody response could be detected but it can be speculated that the animals would have reacted with a booster response.

A very interesting result in this study was the priming of the cellular immune response by a single dose of vaccine in the absence of a measurable antibody response. Kerkhofs and colleagues [20] also reported that the cellular immune response, determined by lymphoproliferation, was induced by the same inactivated BRSV vaccine. When discussed in the literature, the role of CD8 cells in BRSV infection is very controversial. While it has been reported that CD8 responses of animals vaccinated with a different inactivated BRSV vaccine did not protect against immunopathology [28], these immune cells seem to play a key role in the control of infection in calves [29]. This is consistent with the reduction of virus excretion with nasal discharge in vaccinated animals when compared to control animals in the study reported here. This result can be considered a key finding in the study, as a reduction in the excretion of challenge virus i) reflects the replication of the virus indicating that the vaccine is protective and ii) is of practical relevance because reduced virus shedding will also limit the risk of infection for in-contact animals.

Post mortem examinations were performed on two different days (7 or 10 days after infection) as it was expected that hardly any BRSV virus would be detectable more than 1 week after infection, while lung pathology would typically develop around 10 days after infection. In general the results of BRSV re-isolation and lung pathology in this study were in line with these expectations.

BRSV was re-isolated from samples of different organs from the respiratory tract of all control animals and from four out of five vaccinated animals. The overall number of positive samples was lower in the vaccinated group indicating that BRSV replication was reduced after vaccination.

This observation was also reflected by the lung pathology. Macroscopic and histological findings in vaccinated animals were minor and not comparable with the findings in lung sections of BRSV infected unvaccinated animals. From the results obtained it cannot be excluded that other pathogenic agents like Mh were also involved. The vaccine also contains Mh antigen and therefore also protects against this pathogen.
In general, more virus could be isolated from the animals euthanised seven days after infection while lung pathology seemed to be more severe in the animals euthanised at 10 days after infection. It has been reported earlier that lung pathology in BRSV infection is the consequence of immuno-pathological events rather that direct damage of the virus to the tissues [29].

Conclusion

From the results described, it can be concluded that, a single vaccination with an inactivated BRSV vaccine was able to break through the maternal immunity and induce partial protection in very young calves. It can be speculated that the level and duration of the protection will improve once a second dose of vaccine is given. Therefore under field conditions the recommended vaccination schedule of two doses must be administered.

Acknowledgements

The authors would like to thank M. Smit and her colleagues from the animal service department for their excellent technical undertaking of the study and M. Timmermans for assistance at the laboratory testing.

Author details
1 Virological RD Department, Intervet International b.v., Wim de Koeverstraat 35, NL-5831 AN, Boxmeer, the Netherlands. 2 Quality Management Biologicals Department, Intervet International b.v., Wim de Koeverstraat 35, NL-5831 AN, Boxmeer, the Netherlands. 3 Global Ruminant Business Unit, Intervet International b.v., Wim de Koeverstraat 35, NL-5831 AN, Boxmeer, the Netherlands.

Authors’ contributions
MvdS and BM designed the experiments, MvdS and EK performed the experiment, MvdS, EK and BM analyzed the data. BM drafted the manuscript. All authors read and approved the final manuscript.

Competing interests
All authors are employees of Intervet/Schering-Plough Animal Health, the company that markets the vaccine that has been used in the studies reported herein. The article processing charge is payed by Intervet/Schering-Plough Animal Health.

Received: 14 August 2009 Accepted: 11 January 2010 Published: 11 January 2010

References
1. Baker JC. The clinical manifestation of bovine viral diarrhea infection. Vet Clin N Am Food Animal Practice 1995, 11:235-44s.
2. BabuA, LAwman M, Ohrmann HB. Viral-bacterial synergistic interaction in respiratory disease. Adv Virus Res 1988, 32:219-249.
3. Castleman WL, Lay JC, Dubovi EJ, Slauson DO. Viral-bacterial synergistic interaction. Vet Clin N Am Food Animal Practice 1995, 11:235-44s.
4. Czieskiwski DK, Baker JC, Slocombe RF, Reindel JD, Haines DM, Clark EG. Experimental reproduction of respiratory tract disease with bovine respiratory viral infection. Vet Microbiol 1991, 28:39-60.
5. Knott R, Weynants V, Wairavan K, Poel van der WHM, Kramps JA, Letesson JJ. Immune response of calves experimentally infected with non-cell-culture-passaged bovine respiratory syncytial virus. Arch Virol 1998, 143:1119-128.
6. Jønneskjo K, Uttenwehl A, Vold B, Larsen LE, Rontved C, Ronsholt L. An experimental infection model for reproduction of calf pneumonia with bovine respiratory syncytial virus (BRSV) based on one combined exposure of calves. Research in Veterinary Science 2003, 74:55-65.
7. Poel Van der WHM, Kramps JA, Middel WG, Van Oirschot JT, Brand A. Dynamics of bovine respiratory viral infections: a longitudinal epidemiological study in dairy herds. Archis of Virology 1993, 133:309-321.
8. De Jong MC, Poel van der WHM, Brand A, Van Oirschot JT. Quantitative investigation of population persistence and recurrent outbreaks of bovine respiratory viral infection on dairy farms. J Vet Res 1996, 57:628-633.
9. Larsen LE, Vold B. Extensive sequence divergence among bovine respiratory viral isolates. Journal of Clinical Microbiology 2000, 38:4222-4227.
10. Babiuk LA, Lawman MJ, Ohmann HB. The clinical manifestation of bovine viral diarrhea infection. J Vet Res 1999, 66:197-207.
11. Stott EJ, Thomas LH, Taylor G, Collins AP, Jeffert J, Crouch S. A comparison of three vaccines against respiratory viral infection in calves. Journal of Hygiene 1984, 93:251-261.
12. Hägglund H, Hu LF, Larsen LE, Hakhverdyan M, Valarcher JF, Taylor G, et al. Bovine respiratory viral infection ISD-MSIP-segregation in the presence of maternal antibodies. Vaccine 2004, 23:646-655.
13. Schmidt U, Beyer J, Poluster U, Gerschwin LJ, Buchbolz UJ. Mucosal immunization with live recombinant bovine respiratory viral infection (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. J Virol 2002, 76:12355-12359.
14. Simeus EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory viral infection in calves: a systematic overview with emphasis on respiratory viral infection subunit vaccines. Vaccine 2001, 20:954-960.
15. Taylor G, Bruce C, Barbet AF, Wyld SG, Thomas LH. DNA vaccination against respiratory viral infection in young calves. Vaccine 2005, 23:1242-1250.
16. Taylor G, Thomas LH, Furze JM, Cook RS, Wyld SG, Lerch R, et al. Recombinant vaccinia viruses expressing the F, G or N, but not the M2 protein of bovine respiratory viral infection (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions. J Gen Virol 1997, 78:3195-3206.
17. Taylor G, Rijswijk FA, Thomas LH, Wyld SG, Gaddum RM, Cook RS, et al. Resistance to bovine respiratory viral infection (BRSV) induced in calves by a recombinant bovine herpes-virus-1 expressing the attachment glycoprotein of BRSV. J Gen Virol 1998, 79:1759-1767.
18. Kimman TG, Zimmer GM, Westenbrink F, Mars J, van Leeuwen E. Epidemiological study of bovine respiratory viral infection in calves: influence of maternal antibodies on the outcome of disease. Vet Res 1988, 12:104-109.
19. Mawhinney IC, Burrows MR. Protection against bovine respiratory viral infection challenge following a single dose of vaccine in young calves with maternal antibody. Vet Rec 2005, 156:139-143.
20. Kerkhofs P, Tignon M, Petry H, Mawhinney I, Sustronk B. Immune responses to bovine respiratory viral infection (BRSV) following use of an inactivated BRSV-PI3-Mannheimia haemolytica vaccine and a modified live BRSV-BVDV vaccine. Vet J 2004, 167:209-210.
21. Vangrel J, Antonis AF, Fliess M, Petters AF, Harmeyer SS. Efficacy of a modified live bovine respiratory viral infection vaccine in three-week-old calves experimentally challenged with BRSV. Cattle Practice 2005, 13:263-271.
22. Peters AR, Thevasagayam SJ, Wiman A, Salt JS. Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3, BVDV, and BRSV in experimentally infected calves. Prev Vet Med 2004, 66:63-77.
23. Patel JR. Evaluation of a quadrivalent inactivated vaccine for the protection of cattle against diseases due to common viral infections. J Afr Vet Assoc 2004, 75:137-146.
24. Schreiber P, Matheise JP, Dussa H, Heimann M, Letesson JJ, Coppe P, et al. High mortality rate associated with bovine respiratory viral infection (BRSV) infection in Belgian white calves previously vaccinated with an inactivated BRSV vaccine. J Vet Med B 2000, 47:535-550.
25. Antonis AF, Schrijver RS, Daus F, Steverink PJ, Stockhofe N, Hensen EJ, et al. Vaccine-induced immunopathology during bovine respiratory syncytial
virus infection: exploring the parameters of pathogenesis. J Virol 2003, 77:12067-12073.

26. Mohanty SB, Rockemann DO, Davidson JP, Sharabrin OL, Forst SM: Effect of vaccinal serum antibodies on bovine respiratory syncytial viral infection in calves. Am J Vet Res 1981, 42:881-883.

27. West K, Ellis J: Functional analysis of antibody responses of feedlot cattle to bovine respiratory syncytial virus following vaccination with mixed vaccines. Can J Vet Res 1997, 61:28-33.

28. Antonis AF, Claassen EA, Hensen EJ, de Groot RJ, Groot-Mijnes JD, Schrijver RS, et al: Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection. Vaccine 2006, 24:1551-1561.

29. Taylor G, Thomas LH, Wyld SG, Furze J, Sopp P, Howard CJ: Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. J Virol 1995, 69:6658-6664.

doi:10.1186/1746-6148-6-2

Cite this article as: van der Sluijs et al: A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody. BMC Veterinary Research 2010 6:2.